Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chronic stress and immunotherapy response in metastatic melanoma
NL-OMON55104Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of pembrolizumab, nivolumab and ipilimumab in melanoma, sponsored by Leiden University Medical Center. Primary endpoints: Association between chronic stress and treatment response at 3 months and Association between chronic stress and treatment response at 6 months. Started Jan 2020; status: recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON55104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55104.